With the first wave of Alzheimer’s disease drugs reaching the market, investors continue to seek out the next big advance in ...
The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline ...
The Food and Drug Administration approved a new Eli Lilly drug this month that treats Alzheimer's disease. Kisunla is an IV ...
Lantheus is expanding its holdings of PET imaging agents for Alzheimer’s disease, with the acquisition of Meilleur ...
Such tests are likely to play a role in qualifying patients for treatment with anti-amyloid therapies, including Eisai and Biogen's Leqembi (lecanemab), which was approved by the US Food and Drug ...
The new drug, Kisunla, has the potential to be a blockbuster for the company and generate billions in revenue. But despite ...
Sinar Daily on MSN2d
New Alzheimer’s treatment approved by US FDAL OS ANGELES - The US Food and Drug Administration (FDA) has approved a new Alzheimer's treatment from American ...
The latest drug is showing promising results for adults with early Alzheimer's symptoms, mild cognitive impairment (MCI), and ...
The Food and Drug Administration last week approved donanemab, or Kisunla, an intravenous treatment for early stage Alzheimer ...
Following this month's FDA approval of Eli Lilly’s amyloid-busting antibody Kisunla (donanemab), the Alzheimer’s disease ...
LEXINGTON, Ky. (WKYT) - The FDA approved a new drug for patients in the early stages of Alzheimer’s. Eli Lilly’s new medicine ...
Recently, a new drug was approved by the FDA to slow the decline in memory and thinking abilities. One of those affected is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback